Dataset from AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC, SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2 - <18 YEARS OF AGE
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009195
下载链接
链接失效反馈官方服务：
资源简介：
The primary purpose of this study is to determine the pharmacokinetic properties (what the
body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1
infected children and adolescents. This study will also determine whether maraviroc is safe
to use in children and adolescents.
创建时间：
2024-11-27
